leisure time -WSS

leisure time

author：fashion 2025-09-06 06:16:52 - browse：568

he exterior of the U.S. Capitol building is seen at sunrise — Sarah Silbiger/Getty Images

WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

explore

WSS

NIH tests clinical research in primary care with $30 million program

Deposition: Sackler embraced plan to conceal OxyContin’s strength

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

States should stop sabotaging methadone treatment reform

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Abortion pill Supreme Court ruling could impact entire drug industry

explore

leisure time

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Patient advocates debate FDA's accelerated approval process

Drug repurposing or repositioning? The language matters

States should stop sabotaging methadone treatment reform

Guidelines to prevent youth baseball injuries need more muscle

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

At least 13 dead in Texas as scorching temps continue

Abortion pill Supreme Court ruling could impact entire drug industry

Jerome Adams on the need for new antivirals for Covid

Roche subsidiary Foundation Medicine opens new headquarters

focus

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

STAT Virtual Event: ASCO Recap, Live!

States should stop sabotaging methadone treatment reform

Readout LOUD podcast: mifepristone case, GLP

explore

explore

focus

focus